English (United Kingdom)Deutsch (DE-CH-AT)
Nanopatch-Technologie (Impfpatchtechnologie der Firma Vaxxas)

The Nanopatch™ approach consists of an array of thousands of vaccine-coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface.

The central element of this technology is the Nanopatch™ array itself which consists of a 1 cm2 square of silicon with ~20,000 microprojections on its surface - invisible to the naked eye. The Nanopatch™ array penetrates through the protective outer skin layer (stratum corneum) and targets immune-activating material to the immune-cell rich layers just beneath the outermost skin layer utilising the microprojections with optimised spacing and length. The result, demonstrated in a mouse model, is an effective increase in immunogenicity, which can be leveraged for two different purposes: either reducing the dose required to achieve efficacy (100-fold reduction has been achieved in the mouse model when delivering Fluvax®), and for amplifying the vaccine efficacy. Pre-clinical experiments have also shown the ability of the Nanopatch™ to remove or significantly reduce the amount of adjuvant required for effective vaccination.

Traditionally, microneedle delivery systems have been held back from commercialisation due in part to challenges in manufacture scaling. Even in early research programs within Professor Kendall's laboratory, this consideration was always at the forefront of new process developments. At Vaxxas today personnel in both our technical and commercial camps - and those spanning both - are confident that we have a technology which is inherently simple and feasible for high throughput, cost effective manufacture.


Leiter des Ped Mind Institutes
Stefan Bittmann, M.D., M.A.
Weissenstein A, Villalon G, Luchter E, Bittmann S:
“Pipeline bandage with marigold essence in pediatric bee sting lesions”
Applied Medical Research 1 (1):32-34, 2015
» publication download

Weissenstein A, Villalon G, Luchter E, Bittmann S:
Tumor suppressor candidate 3 gene (TUSC 3) deletion correlates with mental retardation in a child”
Applied Medical Research 1 (1): 35-36, 2015
» publication download

Weissenstein A, Villalon G, Luchter E, Bittmann S:
“A newborn with a missing cerebrum”
Applied Medical Research (1):37-38, 2015
» publication download

Weissenstein A, Luchter E, Bittmann S
"Successful treatment of infantile haemangioma with propranolol"
accepted for publication, British Journal of Nursing 02/2015
» publication download

Weissenstein A, Luchter E, Bittmann S:
"Alice in Wonderland Syndrome: a rare neurological manifestation with microscopy in a 6 years old child"
accepted for publication in: Journal of Pediatric Neurosciences 12/2014
» publication download

Weissenstein A, Villalon G, Luchter E, Bittmann:
"Vaccine patches in pediatrics: future or false hope?"
International Journal of Innovative Medicine and Health Sciences (UK), Vol.2, 6-10, 2014
» publication download